NVZMY:OTCMKTS
NOVONESIS NOVOZYMES B Unsponsored Denmark ADR
$67.10
arrow_upward
+1.19%(+0.79) 1D
Oct 14, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVZMY...
Open
$66.21
High
$67.51
Low
$66.18
Mkt. cap
183.47B
Avg. vol.
23.74K
Volume
25.72K
52-wk high
$75.26
52-wk low
$49.90
Beta
0.87
Shares outstanding
414.56M
No. of employees
11K
Open
$66.21
High
$67.51
Low
$66.18
Mkt. cap
183.47B
Avg. vol.
23.74K
Volume
25.72K
52-wk high
$75.26
52-wk low
$49.90
Beta
0.87
Shares outstanding
414.56M
No. of employees
11K
News stories
From web sources and news partners
BigGo Finance
·
8 minutes ago
U.S. Stocks: Nasdaq Tumbles 496 Points as September CPI Acceleration Reignites Rate-Hike Bets
Bloomberg.com
·
57 minutes ago
S&P 500 Ends Longest Streak of Calm Since 2020 as AI Trade Sinks
TradingView
·
58 minutes ago
The Dow Jones Index Closes 0.18% Lower
Yahoo Finance
·
32 minutes ago
Update: Nasdaq, S&P 500 Fall for Third Straight Session Following Hot CPI Data
Profile
Novonesis is a biotechnology company headquartered in Lyngby, Denmark. Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen.
The company develops enzymes, microbial cultures, and other biological products used in food and beverage production, household products, agriculture, and bioenergy.
The merger, first announced in December 2022, was the largest merger in history between two Danish companies. It would combine Novozymes' industrial-enzyme business with Chr. Hansen's microbial cultures and food-ingredient operations.
The company is publicly traded on Nasdaq Copenhagen and is part of the OMX Copenhagen 25 Index. The company's largest shareholder is Novo Holdings A/S, which is owned by the Novo Nordisk Foundation.
As of 2025, Novonesis has more than 11,000 employees and activities in over 45 countries. Wikipedia
About NOVONESIS NOVOZYMES B Unsponsored Denmark ADR